Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.38 |
| ▸ | ESRRA | P11474 | 2/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 6/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508141 | 0.92 | ESRRA (0.38) | NOTUMESRRAGPR142BRAFHDAC8 | |
| SCHEMBL4478022 | 0.81 | RXRA (0.37) | NOTUMBRAF | |
| SCHEMBL4466806 | 0.80 | BRAF (0.41) | BRAF | |
| SCHEMBL1404606 | 0.80 | NR1I2 (0.36) | ESRRABRAFCA12CA1CA2 | |
| SCHEMBL4501468 | 0.80 | BRAF (0.34) | NOTUMESRRABRAF | |
| SCHEMBL1404510 | 0.78 | BRAF (0.33) | BRAFCA12CA1CA2CA9 | |
| SCHEMBL4462964 | 0.78 | BRAF (0.33) | NOTUMGPR142BRAF | |
| SCHEMBL4462247 | 0.78 | ESRRA (0.38) | NOTUMESRRAGPR142BRAFHDAC8 | |
| SCHEMBL4471365 | 0.78 | BRAF (0.33) | NOTUMESRRABRAF | |
| SCHEMBL4467274 | 0.78 | GPR119 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692116-B1 | 1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMA (US) | 2011-03-09 | — | — | EP | claimed |
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | claimed |
| EP-1567507-B1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-06-14 | — | — | EP | claimed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | claimed |
| US-7569568-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070032492-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1567507-B1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | NOTUM 3901/4885ESRRA 227/4885GPR142 1586/4885 |
| US-20070032492-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1RN | NOTUM 4315/4885ESRRA 290/4885GPR142 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.